Anstalt für Zellforschung · Liechtenstein · Since 1958
Our brands, proven at scale — across Europe and Latin America.
Nervinetten®, EMASEX® and Zellaforte® — more than 16 million products sold from Liechtenstein into European and Latin American markets, accessible in over 22 countries through partners. The same system carries partner products to market.
Our brands
Three brands, built and run from Liechtenstein.
Authorised medicine and science-led consumer health, commercialised pharmacy-first — our own portfolio, not licensed in.
-
Rest & Calm · OTC Phytopharma -
Men’s & Women’s Health -
Longevity & Daily Performance
16 m+ products sold across our brands · company figures
Explore the brandsFor your product
Bring your product to the European market.
Market access, regulatory and quality coordination, and commercialisation — one accountable operator.
- Regulatory route settled before budgets scale
- Product-specific quality responsibilities
- A clear route into the responsible team
Since 1958 operating in regulated European markets
Market access servicesOur brands
Built over decades.
Run with discipline.
Three distinct health brands, each with its own product status, communication and market responsibilities. What we run for our own brands, we operate for partners.
Explore all brands-
01 / 03 · Sleep & Calm
Nervinetten® / Nervinetas®
Established herbal medicinal products for restlessness and sleep disorders, with market-specific product information and responsibilities.
Medicinal products · Switzerland and partner-led Latin American markets
Explore the brand -
02 / 03 · Men’s & Women’s Health
EMASEX®
A specialised portfolio of authorised medicine and food supplements, managed with a clear separation of claims and product status.
Medicine + supplements · DACH and partner-led market activity
Explore the brand -
03 / 03 · Longevity & Daily Performance
Zellaforte®
Science-led food supplements built around documented ingredients and permitted health-claim communication.
Food supplements · current portfolio led by KeraBiotic®
Explore the brand
A quality organisation, not a promise.
Certified where it counts: GMP manufacturing and GDP distribution for the EEA and Switzerland, behind products registered with the national authorities of every market they reach.
- founded in Vaduz, Liechtenstein
- 1958
- products sold — company figures
- 16 m+
- active countries
- 6
- countries accessible through partners
- 22+
-
GMP & GDP certificates
Manufacturing & distribution
A GMP-certified quality system for manufacturing and GDP-compliant wholesale and distribution for the EEA and Switzerland, authorised by the Office of Public Health, Principality of Liechtenstein. Current certificates are shared during partner due diligence.
-
Swissmedic · BfArM · AGES
Registrations
Medicinal products registered with Swissmedic (authorisation no. 53253), BfArM in Germany and AGES in Austria, and with the national authorities in Ecuador and Bolivia.
-
GMP · IFS Food
Manufacturing network
Contract manufacturing with some of the largest pharmaceutical producers, in German GMP-certified facilities.
Market access, end to end.
From dossier to pharmacy shelf — access, regulatory coordination, quality and commercialisation for partner products, with the same operating discipline applied to AFZ brands.
All services
- Access Market strategy, regulatory coordination and partner set-up for European launches.
- Quality Documented quality controls — specifications, supplier qualification, batch records and traceability.
- Supply The whole chain under GDP — warehousing, logistics and distribution through to the wholesaler.
- Commercialise Brand building, pharmacy and retail execution, licensing and local go-to-market.
The company
Anstalt für Zellforschung
A pharmaceutical company in Liechtenstein since 1958 — three own brands, more than 16 million products sold, and a quality organisation partners can audit.
- Founded
- 1958 · Vaduz, Liechtenstein
- Markets
- Europe and Latin America · accessible in 22+ countries via partners
- Distribution partners
- adequapharm · Eurostaga · Schmidts Pharma · AFZ Trogen
Regulatory & market notes.
Regulatory and market notes, written by the people who run it operationally.
Medicine or supplement? The classification question that decides your European launch
The same formula can be a medicinal product in one market and a food supplement in another. Here is how the classification is actually determined — and why it must be settled before packaging design starts.
ReadSwitzerland first, or Germany first? Sequencing a DACH launch
Market size is the wrong first criterion. Regulatory route, pharmacy channel structure and pricing reference effects usually decide the better entry order.
ReadWhat a GDP-compliant distribution chain actually requires
Temperature control is the part everyone knows. Qualification, documentation and recall readiness are where audits are lost.
Read
For product owners
Bring your product to Europe.
Product, target markets, timeline — you get a clear next step, not a brochure.
Start a market-access enquiryFor distributors & licensees
Work with our brands.
Licensing and distribution territories are discussed case by case, with quality documentation available up front.
Discuss licensing & distributionEnquiries go directly to the responsible person in Vaduz.